Compare Stocks: SNGX, MRKR, LGVN, and KZIA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KZIA Novogen	$12.31 +1.2%	$13.31	$4.86 ▼ $17.40	$159.65M	2.14	305,292 shs	414,432 shs
LGVN Longeveron	$6.81 +3.5%	$6.91	$4.75 ▼ $12.30	$21.71M	-0.25	76,661 shs	40,353 shs
MRKR Marker Therapeutics	$1.18 -4.8%	$1.31	$0.83 ▼ $2.46	$19.67M	1.53	80,681 shs	35,306 shs
SNGX Soligenix	$0.38 -0.8%	$0.38	$0.28 ▼ $3.07	$5.63M	1.92	236,353 shs	108,826 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KZIA Novogen	0.00%	-9.35%	+0.65%	+12.01%	+53.30%
LGVN Longeveron	0.00%	+1.34%	-11.96%	-6.71%	-16.53%
MRKR Marker Therapeutics	0.00%	-13.87%	+5.36%	-16.90%	+36.18%
SNGX Soligenix	0.00%	+0.85%	+0.32%	-14.28%	-87.66%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KZIA Novogen	$12.31 +1.2%	$13.31	$4.86 ▼ $17.40	$159.65M	2.14	305,292 shs	414,432 shs
LGVN Longeveron	$6.81 +3.5%	$6.91	$4.75 ▼ $12.30	$21.71M	-0.25	76,661 shs	40,353 shs
MRKR Marker Therapeutics	$1.18 -4.8%	$1.31	$0.83 ▼ $2.46	$19.67M	1.53	80,681 shs	35,306 shs
SNGX Soligenix	$0.38 -0.8%	$0.38	$0.28 ▼ $3.07	$5.63M	1.92	236,353 shs	108,826 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KZIA Novogen	0.00%	-9.35%	+0.65%	+12.01%	+53.30%
LGVN Longeveron	0.00%	+1.34%	-11.96%	-6.71%	-16.53%
MRKR Marker Therapeutics	0.00%	-13.87%	+5.36%	-16.90%	+36.18%
SNGX Soligenix	0.00%	+0.85%	+0.32%	-14.28%	-87.66%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KZIA Novogen	2.71	Moderate Buy	$27.33	122.04% Upside
LGVN Longeveron	2.00	Hold	$80.00	1,074.74% Upside
MRKR Marker Therapeutics	2.25	Hold	$10.00	747.46% Upside
SNGX Soligenix	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest SNGX, MRKR, LGVN, and KZIA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	MRKR Marker Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/1/2026	KZIA Novogen	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$34.00 ➝ $40.00
8/25/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	MRKR Marker Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	MRKR Marker Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	KZIA Novogen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$29.00
8/11/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/6/2026	MRKR Marker Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	KZIA Novogen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	SNGX Soligenix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KZIA Novogen	$30K	5,322.02	N/A	N/A	($5.34) per share	-2.31
LGVN Longeveron	$1.20M	18.10	N/A	N/A	$3.26 per share	2.09
MRKR Marker Therapeutics	$3.55M	5.54	N/A	N/A	$0.73 per share	1.62
SNGX Soligenix	N/A	N/A	N/A	N/A	$0.45 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KZIA Novogen	-$13.41M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LGVN Longeveron	-$22.70M	-$9.90	N/A	N/A	N/A	-1,977.59%	-223.19%	-150.20%	11/3/2026 (Estimated)
MRKR Marker Therapeutics	-$12.16M	-$0.41	N/A	N/A	N/A	-343.03%	-56.96%	-47.82%	11/12/2026 (Estimated)
SNGX Soligenix	-$11.08M	-$0.98	N/A	N/A	N/A	N/A	-180.25%	-107.46%	11/6/2026 (Estimated)

Latest SNGX, MRKR, LGVN, and KZIA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	MRKR Marker Therapeutics	-$0.25	-$0.09	+$0.16	-$0.09	$0.68 million	N/A
8/12/2026	Q2 2026	LGVN Longeveron	-$1.75	-$1.90	-$0.15	-$0.19	$0.33 million	$0.29 million
8/7/2026	Q2 2026	SNGX Soligenix	-$0.1550	-$0.12	+$0.0350	-$0.12	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KZIA Novogen	N/A	N/A	N/A	N/A	N/A
LGVN Longeveron	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A
SNGX Soligenix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KZIA Novogen	N/A	2.87	N/A
LGVN Longeveron	N/A	2.63	2.63
MRKR Marker Therapeutics	N/A	6.03	6.03
SNGX Soligenix	N/A	2.77	2.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KZIA Novogen	30.89%
LGVN Longeveron	10.01%
MRKR Marker Therapeutics	22.39%
SNGX Soligenix	3.60%

Insider Ownership

Company	Insider Ownership
KZIA Novogen	1.00%
LGVN Longeveron	7.42%
MRKR Marker Therapeutics	5.70%
SNGX Soligenix	1.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KZIA Novogen	12	12.97 million	12.84 million	No Data
LGVN Longeveron	20	3.19 million	2.95 million	Not Optionable
MRKR Marker Therapeutics	60	16.67 million	15.72 million	Not Optionable
SNGX Soligenix	20	14.82 million	14.54 million	Not Optionable

SNGX, MRKR, LGVN, and KZIA Headlines

Recent News About These Companies

SNGX: Applying for Vaccine Development Funding for Ebola Vaccine

August 12, 2026 | finance.yahoo.com

Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

August 7, 2026 | prnewswire.com

Soligenix Expands At-the-Market Equity Offering Capacity

June 26, 2026 | tipranks.com

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

June 8, 2026 | prnewswire.com

Soligenix Expands At-The-Market Equity Financing Capacity

May 28, 2026 | tipranks.com

SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail Frenzy

May 27, 2026 | finance.yahoo.com

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

May 26, 2026 | prnewswire.com

SOLIGENIX, INC.: Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

May 8, 2026 | finanznachrichten.de

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

May 8, 2026 | prnewswire.com

SNGX stock slumps to record low after lymphoma trial fails – all eyes now on Behçet’s disease treatment

April 29, 2026 | msn.com

SNGX phase 3 trial halted on HyBryte

April 29, 2026 | msn.com

SOLIGENIX, INC.: Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte in Treatment of Cutaneous T-Cell Lymphoma

April 28, 2026 | finanznachrichten.de

SNGX phase 3 trial halted — HyBryte setback puts strategy in question

April 28, 2026 | msn.com

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

April 28, 2026 | prnewswire.com

Soligenix (SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach

April 23, 2026 | finance.yahoo.com

Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach

April 23, 2026 | usatoday.com

Soligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

April 20, 2026 | financial-news.co.uk

Soligenix (SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

April 20, 2026 | finance.yahoo.com

Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results

April 17, 2026 | financial-news.co.uk

Soligenix (SNGX) Advances CTCL Research With Interim Analysis, Comparative Study Results

April 17, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNGX, MRKR, LGVN, and KZIA Company Descriptions

Novogen NASDAQ:KZIA

$12.31 +0.15 (+1.23%)

As of 09/4/2026 04:00 PM Eastern

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Longeveron NASDAQ:LGVN

$6.81 +0.23 (+3.50%)

As of 09/4/2026 04:00 PM Eastern

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Marker Therapeutics NASDAQ:MRKR

$1.18 -0.06 (-4.84%)

As of 09/4/2026 04:00 PM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Soligenix NASDAQ:SNGX

$0.38 0.00 (-0.84%)

As of 09/4/2026 03:59 PM Eastern

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SNGX, MRKR, LGVN, and KZIA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SNGX, MRKR, LGVN, and KZIA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SNGX, MRKR, LGVN, and KZIA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNGX, MRKR, LGVN, and KZIA Company Descriptions

Novogen NASDAQ:KZIA

Longeveron NASDAQ:LGVN

Marker Therapeutics NASDAQ:MRKR

Soligenix NASDAQ:SNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SNGX, MRKR, LGVN, and KZIA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SNGX, MRKR, LGVN, and KZIA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SNGX, MRKR, LGVN, and KZIA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNGX, MRKR, LGVN, and KZIA Company Descriptions

Novogen NASDAQ:KZIA

Longeveron NASDAQ:LGVN

Marker Therapeutics NASDAQ:MRKR

Soligenix NASDAQ:SNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools